Various implementations include approaches and systems for isolating acellular biological therapeutics. In a particular implementation, a method includes: drawing leukocyte- and platelet-rich plasma (L-PRP) into a first syringe, passing the L-PRP from the first syringe through a syringe filter to provide filtered L-PRP, drawing the filtered L-PRP into a second syringe, the second syringe having at least one protein precipitating agent (PPA) to provide a L-PRP/PPA mixture, performing a phase separation of protein precipitate and liquid phase from the L-PRP/PPA mixture, removing the liquid phase to yield a concentrated protein precipitate, passing the concentrated protein precipitate and water through a filtering tube, the filtering tube isolating concentrated protein from the concentrated protein precipitate and water, and collecting the concentrated protein.

Various implementations include approaches and systems for isolating acellular biological therapeutics. In a particular implementation, a method includes: drawing leukocyte- and platelet-rich plasma (L-PRP) into a first syringe, passing the L-PRP from the first syringe through a syringe filter to provide filtered L-PRP, drawing the filtered L-PRP into a second syringe, the second syringe having at least one protein precipitating agent (PPA) to provide a L-PRP/PPA mixture, performing a phase separation of protein precipitate and liquid phase from the L-PRP/PPA mixture, removing the liquid phase to yield a concentrated protein precipitate, passing the concentrated protein precipitate and water through a filtering tube, the filtering tube isolating concentrated protein from the concentrated protein precipitate and water, and collecting the concentrated protein.

The invention is directed to a composition comprising a fibrin hydrogel conjugated to peptides of laminin-111 (L1) and methods for repairing damaged salivary tissue using the composition.

The invention is directed to a composition comprising a fibrin hydrogel conjugated to peptides of laminin-111 (L1) and methods for repairing damaged salivary tissue using the composition.

Described herein are compositions and techniques related to generation and therapeutic application of artificial synapses. Artificial synapses are engineered extracellular vesicles, including exosomes, which incorporate sticky binders on their surface to anchor signaling domains against biological targets, such as receptors. These engineered additives can be organized in genetic vector constructs, expressed in mammalian cells, wherein the sticky binders attach to extracellular vesicles such as exosomes, thereby presenting their joined signaling domains which are rapidly taken up by recipient cells. Artificial synapses adopt the hallmark biophysical and biochemical features of extracellular vesicles, allowing for rapid deployment and scale-up. Importantly, this strategy can allow for kinetically favorable signal generation and signal propagation. This includes, for example, increasing density of agonist presentation to support receptor clustering—an onerous barrier for traditional receptor targeting strategies.

There is provided inter alia an isolated polynucleotide, wherein the polynucleotide encodes a polypeptide selected from the group consisting of: (a) a polypeptide having the amino acid sequence according to SEQ ID NO: 1, (b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 80% identical over its entire length to the amino acid sequence of SEQ ID NO: 1, and (c) a polypeptide having the amino acid sequence according to SEQ ID NO: 3.

There is provided inter alia an isolated polynucleotide, wherein the polynucleotide encodes a polypeptide selected from the group consisting of: (a) a polypeptide having the amino acid sequence according to SEQ ID NO: 1, (b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 80% identical over its entire length to the amino acid sequence of SEQ ID NO: 1, and (c) a polypeptide having the amino acid sequence according to SEQ ID NO: 3.

The present invention provides biological molecules for use in detecting, identifying and/or removing microbes and microbial components; diagnostic, therapeutic and filtration devices comprising the biological molecules; and systems and methods for treating fluids using the biological molecules and devices of the invention.

The present invention relates to the use of a fibrinogen capture agent or a fibrinogen detection agent in an assay to detect a Ciz1 b-variant.

The present invention relates to the use of a fibrinogen capture agent or a fibrinogen detection agent in an assay to detect a Ciz1 b-variant.